← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2004First marketed drug
Nov 29, 2012First NDA
Nov 29, 2012Last known activity
Jun 2, 2026
Timeline
1990s
- Nov 15, 1994
Exelixis— Founded
2000s
- Nov 20, 2001
Genomica— Acquired
2010s
- Nov 29, 2012
cabozantinib— NDA Organization
Drugs by trial phase (66 distinct, 153 trials)
Phase 4 (2 own, 0 via acquisition)
Phase 3 (14 own, 0 via acquisition)
Phase 2 (16 own, 0 via acquisition)
Phase 1 (34 own, 0 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Adenocarcinoma, Follicular
- Adrenocortical Carcinoma
- Albuminuria
- Astrocytoma
- Basal Cell Carcinoma
- Bile Duct Neoplasms
- Breast Neoplasms
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Merkel Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Papillary
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Carotid Body Tumor
- Cholangiocarcinoma
- Colorectal Neoplasms
- Diabetic Nephropathies
- Digestive System Neoplasms
- Endometrial Neoplasms
- Esophageal Neoplasms
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumors
- Glioblastoma
- Gliosarcoma
- Hematologic Neoplasms
- Kidney Diseases
- Kidney Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Liver Diseases
- Lung Neoplasms
- Melanoma
- Multiple Myeloma
- Myeloproliferative Disorders
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Neuroendocrine Tumors
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Paraganglioma
- Pheochromocytoma
- Philadelphia Chromosome
- Polycythemia
- Polycythemia Vera
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Primary Myelofibrosis
- Prostatic Neoplasms
- Renal Insufficiency
- Sarcoma
- Skin Neoplasms
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Thrombocythemia, Essential
- Thrombocytosis
- Thyroid Cancer, Papillary
- Thyroid Diseases
- Thyroid Neoplasms
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
- Urologic Neoplasms
- Uterine Cervical Neoplasms
- Uveal Neoplasms
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT07283731CollaboratorPhase 2Jun 2, 2026
- NCT07218666CollaboratorPhase 2May 31, 2026
- NCT07193550CollaboratorPhase 2May 31, 2026
- NCT07187869CollaboratorPhase 1Mar 31, 2026
- NCT07226063CollaboratorPhase 2Feb 28, 2026
- NCT06926634CollaboratorPhase 2Dec 31, 2025
- NCT07227402CollaboratorPhase 3Dec 29, 2025
- NCT06794229CollaboratorPhase 2Nov 30, 2025
- NCT06968988CollaboratorPhase 1Nov 30, 2025
- NCT07185945CollaboratorPhase 2Nov 30, 2025
- NCT06937866CollaboratorPhase 1/Phase 2Nov 12, 2025
- NCT06957431CollaboratorPhase 1Oct 22, 2025
- NCT07043608CollaboratorPhase 2Sep 30, 2025
- NCT06912087CollaboratorPhase 1Sep 29, 2025
- NCT07123103Lead sponsorPhase 1Aug 18, 2025
Details
- Founded
- Cambridge, MA, US Nov 15, 1994
- First NDA
- Nov 29, 2012
- Last known activity
- Jun 2, 2026
Designations held
- Orphan drug
- Fast track
- Priority review